A Texas House committee on Wednesday approved a bill to significantly expand the state’s medical marijuana program.
Monthly marijuana sales exceeded $100 million for the first time in Illinois in March, shattering the previous record.
Mind Cure announces a CAD$10 million bought deal financing at a unit price of CAD$0.60. Proceeds will be directed toward product research development and related tech initiatives like its iSTRYM digital therapeutics platform.
Mind Cure Health will be focus its psychedelics R&D on psilocybin, ketamine and ibogaine. The Company will pursue both pain-based and mental health applications.
Given that psychedelics micro-dosing has several commercial advantages, here are two companies that investors should look at.
Psychedelics micro-dosing offers several key advantages over psychedelic drug applications centered around heavier dosages.
In the months leading up to the presidential election, markets may renew their bullishness in companies that sell marijuana.
Aphria Inc., a global cannabis company, has announced that it will transfer its stock exchange listing from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq).
As Summer fast approaches, it seems as though gains are continuing to enter into the cannabis industry.
CBN is poised to be the next cannabis trend. It could join the ranks of terpenes, cannabis for pets, or maybe even CBD.